Alkaptonuria is a genetic condition. It affects how your body breaks down certain proteins. This leads to a buildup of a special acid in your urine, causing dark urine and joint problems.
Every report comes from a Lived member, sent anonymously.
Have you had Hip Replacement for Alkaptonuria?
Alkaptonuria (AKU) is a rare inherited condition in which the body cannot fully break down two amino acids, phenylalanine and tyrosine, that come from protein. A substance made partway through that process, homogentisic acid, builds up instead. The body clears much of it in the urine, which is why urine in alkaptonuria turns dark brown or black when it is left standing and exposed to air. What remains settles in connective tissue such as cartilage, tendons and ligaments, slowly staining it blue-black. This pigment buildup is called ochronosis. It often shows first as dark spots in the whites of the eyes, darkened ear cartilage or bluish patches on the hands, usually after age 30. Over time the stained tissue becomes stiff and brittle, which leads to the condition's main burden: early, progressive arthritis of the spine and large joints such as the hips, knees and shoulders. Alkaptonuria can also affect heart valves, the kidneys and prostate, tendons and bones.
Alkaptonuria is caused by changes in the HGD gene, which carries instructions for the enzyme that normally breaks homogentisic acid down. It is inherited in an autosomal recessive pattern: a person has the condition only when they receive a nonworking copy of the gene from both parents. Parents who each carry one copy usually have no symptoms. When both parents are carriers, each child has a one in four (25%) chance of having alkaptonuria and a one in two chance of being a carrier. Nothing a person does causes alkaptonuria, and it is not triggered by diet or lifestyle. Those factors can, however, affect how much strain the joints take over the years. The condition affects roughly 1 in 250,000 to 1 million people in the United States and is more common in parts of Slovakia and the Dominican Republic.
The key test measures homogentisic acid in the urine. People with alkaptonuria excrete large amounts of it every day, usually 1 to 8 grams, so a urine test from a specialized metabolic laboratory can establish the diagnosis. Genetic testing that finds changes in both copies of the HGD gene confirms it and makes it possible to test relatives. Many people are diagnosed late. Dark urine may go unnoticed or unexplained for years, and the back and joint pain of alkaptonuria can look like other kinds of arthritis, so some people are treated for another joint disease first. Clues that point toward alkaptonuria include urine that darkens on standing, dark pigment in the eyes or ears, and arthritis that starts unusually early, especially in the spine. Because brothers and sisters of an affected person share the same inheritance risk, testing them is reasonable even if they feel well.
Treatment has two parts: lowering the amount of homogentisic acid the body makes, and managing the damage it causes. Nitisinone is a medicine that blocks an earlier step in the same chemical pathway, so far less homogentisic acid is produced. In the United States, it is approved for adults with alkaptonuria under the brand name Harliku, taken as a tablet once a day. In trials it lowered homogentisic acid in the urine by roughly 90% or more. In a large European trial lasting four years, people taking nitisinone had less pigment buildup and better scores on a combined measure of disease signs, which suggests slower progression. An earlier US trial in people who already had advanced arthritis did not show improvement in hip movement, so nitisinone is best understood as slowing further damage rather than reversing joint changes that are already present. The main trade-off is that blocking this pathway raises the level of tyrosine in the blood. Very high tyrosine can inflame the surface of the eye (the cornea) and, less often, cause painful thickened skin on the palms and soles. For that reason, people starting nitisinone have an eye exam with a slit lamp (the magnifying microscope an eye doctor uses) before treatment and regularly afterward, along with blood tests. A diet lower in protein is not routinely required, but a care team may recommend one, or a pause in treatment, if tyrosine levels climb or eye problems develop. A low-protein diet on its own has not been proven to change the course of alkaptonuria. Managing the effects of the disease matters as much as the medicine. Physical and occupational therapy help maintain strength, flexibility and function, and pain relief is tailored to the person. Many people eventually need hip, knee or shoulder replacement. Kidney or prostate stones may need procedures to remove them, a narrowed aortic valve may need replacement, and an underactive thyroid is treated with thyroid hormone.
Alkaptonuria is lifelong and tends to progress slowly. Dark urine may be the only sign in childhood. Back pain and stiffness often begin in the 20s or 30s, and arthritis in the knees, hips and shoulders follows over the next decades. Many people live with chronic pain and gradually lose some flexibility, particularly in the spine. Tendons, especially the Achilles tendon at the heel and the tendon below the kneecap, can weaken and tear, and bones can thin, raising the chance of fractures. With appropriate medical care, people with alkaptonuria generally have a normal life expectancy, but the condition can significantly affect mobility and work. Protecting the joints is a practical part of daily life. Avoiding heavy manual labor and high-impact sports may reduce strain on the spine and large joints, while regular low-impact activity and physical therapy help keep muscles strong. Follow-up looks for complications before they cause symptoms. After age 40, a heart ultrasound (echocardiogram) is recommended to check the heart valves and the aorta. Thyroid function is checked at diagnosis and every one to two years after that. People taking nitisinone also need ongoing eye exams and blood tests. Care is often coordinated by a specialist in genetic or metabolic conditions working with rheumatology, orthopedics, cardiology and urology.
Arrange an evaluation if urine regularly turns dark on standing, if dark pigment appears in the eyes or ear cartilage, or if back or joint arthritis begins unusually early, especially when a brother or sister has alkaptonuria. Contact your care team promptly for new shortness of breath, chest pain during activity, dizziness or fainting, or swelling in the feet or ankles, since these can signal a heart valve problem. Back or side pain that will not go away, blood in the urine, or fever and chills with urinary symptoms can mean a kidney stone that needs medical care. If you take nitisinone, call your prescriber right away about eye pain, redness, burning or new sensitivity to light, so tyrosine levels and your eyes can be checked.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Alkaptonuria is like, what's helped you, or ask the community a question.